1. Evaluation of 5‐Fluorouracil Metabolic Enzymes as Predictors of Response to Adjuvant Chemotherapy Outcomes in Patients with Stage II/III Colorectal Cancer: A Decision‐Curve Analysis
   Kohei Shigeta et al, 2014, World Journal of Surgery CrossRef
2. Safety of implanting sustained-release 5-fluorouracil into hepatic cross-section and omentum majus after primary liver cancer resection
   Jiangtao Chen et al, 2016, International Journal of Immunopathology and Pharmacology CrossRef
3. Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer
   Elinor Bexe Lindskog et al, 2014, BMC Clinical Pathology CrossRef
4. Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis
   YUJI SHIMAMOTO et al, 2016, International Journal of Molecular Medicine CrossRef
5. Recent Updates on Mechanisms of Resistance to 5-Fluorouracil and Reversal Strategies in Colon Cancer Treatment
   Shamin Azwar et al, 2021, Biology CrossRef
6. Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients
   Emne Ali Abdallah et al, 2015, International Journal of Cancer CrossRef
7. Disseminated carcinomatosis of the bone marrow with disseminated intravascular coagulation as the first symptom of recurrent rectal cancer successfully treated with chemotherapy: A case report and review of the literature
   Hiroshi Takeyama et al, 2017, Oncology Letters CrossRef
8. Predictive value of thymidylate synthase for the prognosis and survival of lung adenocarcinoma patients
   YAN HUANG et al, 2015, Oncology Letters CrossRef
9. IntegratingTYMS,KRASandBRAFtesting in patients with metastatic colorectal cancer
   Anastasios Ntavatzikos et al, 2017, World Journal of Gastroenterology CrossRef
10. Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases
    Hiroshi Takeyama et al, 2018, Molecular and Clinical Oncology CrossRef
11. Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients
    KENSUKE KUMAMOTO et al, 2013, Oncology Letters CrossRef
12. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
    Christina Kline et al, 2013, Pharmaceuticals CrossRef
13. Excision Repair Cross-Complementation group 1 (ERCC1) C118T SNP does not affect cellular response to oxaliplatin
    Lieke H. van Huis-Tanja et al, 2014, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
14. Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E4203)
    Neal J. Meropol et al, 2018, Cancer CrossRef
15. Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update
    Pan Xie et al, 2020, Cellular Oncology CrossRef
16. Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
    Marco Tampellini et al, 2018, Future Oncology CrossRef
17. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma
    Anteneh A. Tesfaye et al, 2019, Journal of Pancreatic Cancer CrossRef
18. TYMS/KRAS/BRAF molecular profiling predicts survival following adjuvant chemotherapy in colorectal cancer
    Anastasios Ntavatzikos et al, 2019, World Journal of Gastrointestinal Oncology CrossRef